ReviewWorld journal of gastroenterology2023
Liver transplantation in the management of cholangiocarcinoma: Evolution and contemporary advances.
Review in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Thirty Years and Beyond: Long-term Outcomes After Liver Transplantation at a Single Center: Progress, Challenges, and Future Implications.Transplantation direct · 2026Article
- Review
- Current Status of Drug Treatment of Cholangiocarcinoma-Updated Progress and Critical Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Transplant Oncology in Evolution: Emerging Roles for Liver Transplant Beyond Hepatocellular Carcinoma.Cancers · 2026Review
- Review
- Therapeutic Advances in Initially Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma: Emerging Treatments and the Role of Liver Transplantation.Current oncology (Toronto, Ont.) · 2025Review
- Cholangiocarcinoma: The era of liquid biopsy.World journal of gastroenterology · 2025Review
- Expanding Indications in Transplant Oncology.Cancers · 2025Review
- Advances in Immunotherapy for Transplant Oncology.Cancers · 2024Article
- Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation.Cancers · 2024Review
- Hepatolithiasis: Epidemiology, presentation, classification and management of a complex disease.World journal of gastroenterology · 2024Review
- Primary sclerosing cholangitis and cholangiocarcinoma: the 2023 practice guidance and future perspectives.Hepatobiliary surgery and nutrition · 2024Article
- Perioperative and palliative systemic treatments for biliary tract cancer.Therapeutic advances in medical oncology · 2024Review
- Role of routine lymph node dissection alongside resection of intrahepatic cholangiocarcinoma: Systematic review and meta-analysis.World journal of gastrointestinal oncology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the biliary epithelium. It may occur at any location along the biliary tree with the perihilar area being the most common. Prognosis is poor with 5-year overall survival at less than 10%, typically due to unresectable disease at presentation. Radical surgical resection with clear margins offers a chance of cure in patients with resectable tumours, but is frequently not possible due to locally advanced disease. On the other hand, orthotopic liver transplantation (LT) allows for a radical and potentially curative resection for these patients, but has been historically controversial due to the limited supply of donor grafts and previously poor outcomes. In patients with perihilar CCA, within specific criteria and following the implementation of a protocol combining neoadjuvant chemoradiation and LT, excellent results have been achieved in the last decades, resulting in its increasing acceptance as an indication for LT and the standard of care in several centres with significant experience. However, in intrahepatic CCA, the role of LT remains controversial and owing to dismal previous results it is not an accepted indication. Nevertheless, more recent studies have demonstrated favourable results with LT in early intrahepatic CCA, indicating that, under defined criteria, its role may increase in the future. This review highlights the history and contemporary advances of LT in CCA, with particular focus on the improving outcomes of LT in intrahepatic and perihilar CCA and future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.